1. Home
  2. UA vs SUPN Comparison

UA vs SUPN Comparison

Compare UA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc. Class C

UA

Under Armour Inc. Class C

HOLD

Current Price

$4.81

Market Cap

3.4B

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$42.03

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UA
SUPN
Founded
1996
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.8B
IPO Year
2005
2010

Fundamental Metrics

Financial Performance
Metric
UA
SUPN
Price
$4.81
$42.03
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$61.60
AVG Volume (30 Days)
2.0M
532.9K
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,966,370,000.00
$392,755,000.00
Revenue This Year
N/A
$22.70
Revenue Next Year
$1.57
$19.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$40.51
52 Week High
$7.91
$59.68

Technical Indicators

Market Signals
Indicator
UA
SUPN
Relative Strength Index (RSI) 37.28 39.52
Support Level $4.70 N/A
Resistance Level $5.26 $52.33
Average True Range (ATR) 0.17 1.26
MACD 0.04 -0.03
Stochastic Oscillator 27.45 36.38

Price Performance

Historical Comparison
UA
SUPN

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: